Highlights Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Delayed Nasdaq Other stock markets 12:01:06 2024-05-09 pm EDT			5-day change	1st Jan Change
0.5374 ^USD	-2.24%		-0.67%	-31.10%

Apr. 25	Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	CI
Mar. 14	Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	Apr. 25	CI
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	Mar. 14	CI
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	Feb. 27	CI
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	Feb. 01	CI
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	Dec. 14	CI
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21	CI
Purple Biotech Reports Potential Biomarker Data Support CM24?s Mechanism of Action	23-10-06	CI
Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer	23-10-03	CI
Purple Biotech Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients	23-07-11	CI
Purple Biotech Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Kitov Pharmaceuticals Holdings Ltd. Submits New Drug Application to FDA for KIT-302	17-07-31	CI
Kitov Pharmaceuticals Holdings Ltd. Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model	17-07-18	CI
Kitov Pharmaceuticals Holdings Ltd. Provides Updates on KIT-302 New Drug Application	17-06-26	CI
U.S. Food and Drug Administration Grants Kitov Pharmaceuticals Holdings Ltd for New Drug Application Filing Fee	17-04-03	CI
Kitov Pharmaceuticals Holdings Ltd. Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2016	17-03-27	CI
Kitov Pharmaceuticals Holdings Ltd Announces License Agreement for Kit-302 in South Korea	17-03-08	CI
Kitov Pharmaceuticals Plans To Acquire Additional Stake in TyrNovo	17-01-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Purple Biotech Ltd Nasdaq

Equities

PPBT

US74638P1093

Highlights

Filters